Ocera Therapeutics, Inc. (NASDAQ:OCRX) moved down -7.74% and closed its last trading session at $1.43. This Medical Sector stock currently has the Market Capitalization of 33.71 Million. The Average Volume for the stock is measured as 2.98 Million. The Stock has a 52-Week High of $3.33 and 52-Week Low of $0.52 following the dates, it touched its 52-Week High on Mar 21, 2016 and 52-Week Low on Feb 7, 2017. Currently, the Return on Assets value for the trailing twelve months is -76.1% with the Return on Equity and Return on Investment of -129.3% and -101.9% respectively. This firm currently has YTD (year to date) performance of -31.9 Percent which is not good. The Short Ratio for the stock is 0.33.
Ocera Therapeutics, Inc. (NASDAQ:OCRX) Price to Earnings (P/E) ratio is 0. EPS or Earning per Share stands at $-1.36. The TTM operating margin is 0 percent.
Ocera Therapeutics, Inc. (NASDAQ:OCRX) reports its Earnings on Thu 9 Mar (10 days ago). The estimated EPS for the current quarter is said to be $-0.34. Following Earnings result, share price were UP 5 times out of last 11 Qtrs. The stock has reduced about -46.3% since it reported its last earnings. The Closing price of Ocera Therapeutics, Inc. (NASDAQ:OCRX) at Last Earnings was $0.66 as compared to the previous closing price of $1.43. The Predicted Move on the 7th day after Ocera Therapeutics, Inc. (NASDAQ:OCRX) will release its earnings at about 5%.
By Looking at Earnings History, Out of 12 Quarters when the Earnings were reported, Ocera Therapeutics, Inc. (NASDAQ:OCRX) beats earnings by 58%, The Stock Missed Earnings 4 times and has met earnings 0 times.
We will discuss the past Quarters Earnings below:
On 03/01/2017, Analysts were suspecting EPS of $-0.35/share where Ocera Therapeutics, Inc. (NASDAQ:OCRX) reported its Actual EPS of $-0.33. Thus showing a Surprise of 5.7 percent. The Closing Price of the stock before earnings was $0.66 while on the Next day the stock closed its trading session at $0.61 with a percentage change of -7.58% from the price of 0.66 before Earnings. The Stock Closing Price on the 7th day of earnings was $0.6.
Ocera Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the development and commercialization of OCR-002, which is in Phase IIb trials for the treatment of hyperammonemia and hepatic encephalopathy in patients with liver cirrhosis, acute liver injury, and acute liver failure, as well as in the areas of unmet medical need. The company is headquartered in Palo Alto, California.